These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 417019)

  • 1. Inhibition of C5 convertase by epsilon amino caproic acid (EACA): a limiting factor in the generation of C5a anaphylatoxin.
    Vallota EH
    Immunology; 1978 Mar; 34(3):439-47. PubMed ID: 417019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of complement fragment C5a in milk is variable among cows.
    Rainard P; Poutrel B
    J Dairy Sci; 2000 May; 83(5):945-51. PubMed ID: 10821569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative inefficiency of terminal complement activation.
    Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
    J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
    Hammer CH; Hänsch G; Gresham HD; Shin ML
    J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3 requirements for formation of alternative pathway C5 convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
    Langone JJ; Das C; Bennett D; Terman DS
    J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terminal complement components play a role in the expression of C5a.
    Gresham HD; Renfer L; Hammer CH; Frank MM
    J Immunol; 1987 Feb; 138(3):838-41. PubMed ID: 3805718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Freeze-thaw activation of the complement attack phase: II. Comparison of convertase generated C--56 with C--56 generated by freezing and thawing.
    Dessauer A; Rother U; Rother K
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():83-8. PubMed ID: 6444196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
    Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
    J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preservation of C3, C5, and C5a functional activities by a new radiolabeling method; demonstration of C5 products in complement-activated serum.
    Kreutzer DL; Kunkel S; Ward PA; Showell H; McLean RH
    J Immunol; 1979 Nov; 123(5):2278-82. PubMed ID: 489983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition by epsilon-aminocaproic acid of the activation of the first component of the complement system.
    Soter NA; Austen KF; Gigli I
    J Immunol; 1975 Mar; 114(3):928-32. PubMed ID: 1167567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.
    DiScipio RG
    Biochem J; 1981 Dec; 199(3):497-504. PubMed ID: 6918218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease.
    Maruo K; Akaike T; Ono T; Okamoto T; Maeda H
    J Allergy Clin Immunol; 1997 Aug; 100(2):253-60. PubMed ID: 9275149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The release of C5a in complement-activated serum does not require C6.
    Biesecker G; Wagner JL; Hugli TE
    J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of immune complex and zymosan-mediated anaphylatoxin generation by proteins B and H of the alternative complement pathway.
    Kings M; Nydegger UE; de Weck AL
    Immunology; 1984 Jan; 51(1):123-31. PubMed ID: 6197357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human platelet-initiated formation and uptake of the C5-9 complex of human complement.
    Zimmerman TS; Kolb WP
    J Clin Invest; 1976 Jan; 57(1):203-11. PubMed ID: 812888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.